TRIMTECH Therapeutics
Cambridge, England, United Kingdom · Biotechnology, Health Care, Therapeutics
TRIMTECH Therapeutics is a biotech company focused on harnessing targeted protein degradation for the treatment of neurodegenerative diseases. The company has developed a pipeline of CNS-penetrant therapeutics based on their unique degrader molecules known as TRIMTACs. By leveraging the properties of the E3 ubiquitin ligase TRIM21, TRIMTECH aims to address significant treatment gaps for conditions
Key facts
- Headquarters
- Cambridge, England, United Kingdom
- Employees
- 21
- Industries
- Biotechnology, Health Care, Therapeutics
- Status
- Private
- Website
- trimtechtherapeutics.com
- Company page
Recent activity at TRIMTECH Therapeutics
- : TRIMTECH extends its seed round to $47M for developing protein degradation drugs, led by Johnson & Johnson Innovation and BGF.
- : Trimtech Therapeutics raises an additional $14M in Seed funding led by Johnson & Johnson Innovation and others to expand operations and development efforts.
- : TRIMTECH Therapeutics raised $31M in a seed funding round led by Cambridge Innovation Capital and SV Health Investors’ Dementia Discovery Fund to advance targeted protein degradation for neurodegenerative diseases.
TRIMTECH Therapeutics funding history
| Date | Round | Amount |
|---|---|---|
| Jun 2026 | Seed | $47.0M |
| Jun 2026 | Seed | $14.0M |
| Mar 2025 | Seed | $31.0M |
Leadership
- Alexander Lex, SVP Head of Chemistry
- Damian Crowther, Head of Research
- Nicki Thompson, Chief Executive Officer
- Andrea Testa, Scientific Co Founder
Verified email and direct lines for TRIMTECH Therapeutics’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.
TRIMTECH Therapeutics in the news
Companies similar to TRIMTECH Therapeutics
- CytoDyn · Biotechnology, Health Care, Therapeutics
- Kynexis · Biotechnology, Health Care, Therapeutics
- PDS Biotech · Biotechnology, Health Care, Therapeutics
- NRx Pharmaceuticals · Biotechnology, Health Care, Therapeutics
- Waypoint Bio · Biotechnology, Health Care, Therapeutics
About TRIMTECH Therapeutics: questions and answers
What does TRIMTECH Therapeutics do?
TRIMTECH Therapeutics is a biotech company focused on harnessing targeted protein degradation for the treatment of neurodegenerative diseases. The company has developed a pipeline of CNS-penetrant therapeutics based on their unique degrader molecules known as TRIMTACs. By leveraging the properties of the E3 ubiquitin ligase TRIM21, TRIMTECH aims to address significant treatment gaps for conditions
Where is TRIMTECH Therapeutics headquartered?
TRIMTECH Therapeutics is headquartered in Cambridge, England, United Kingdom.
How many employees does TRIMTECH Therapeutics have?
TRIMTECH Therapeutics has about 21 employees.
Has TRIMTECH Therapeutics raised funding?
Yes. Fundz has recorded 3 funding events for TRIMTECH Therapeutics. The most recent, Seed of $47.0M, was in Jun 2026.
Who leads TRIMTECH Therapeutics?
Nicki Thompson is a Chief Executive Officer at TRIMTECH Therapeutics.
What is the latest news on TRIMTECH Therapeutics?
On Jun 23, 2026, TRIMTECH extends its seed round to $47M for developing protein degradation drugs, led by Johnson & Johnson Innovation and BGF.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy